Oxitres Tablet contains Acetylcysteine 600 mg, a mucolytic agent primarily used to reduce the viscosity of bronchial secretions in respiratory conditions characterized by excessive or thick mucus production. Acetylcysteine acts by breaking down disulfide bonds in mucoproteins, thereby decreasing mucus thickness and facilitating expectoration. This enhances airway clearance and improves respiratory function in patients with chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, and other pulmonary disorders. Additionally, Acetylcysteine serves as an antidote in acetaminophen (paracetamol) overdose by replenishing intracellular glutathione stores, thus preventing hepatic damage. Oxitres Tablet is administered orally and is generally well tolerated; however, patients may occasionally experience gastrointestinal disturbances such as nausea, vomiting, or abdominal discomfort. Caution is advised in individuals with asthma or hypersensitivity to Acetylcysteine. It is important to use Oxitres under medical supervision, adhering to prescribed dosages to optimize therapeutic outcomes. The tablet formulation ensures convenient dosing and patient compliance. Overall, Oxitres Tablet is an effective pharmaceutical option for managing mucus-related respiratory conditions and acetaminophen toxicity, contributing to improved patient respiratory health and safety.